Biogen Idec CEO George Scangos discusses the busy year ahead for the company, including the EU launch of Tecfidera and when a dividend will be offered.
Eli Lilly Chairman & CEO John Lechleiter provides insight on its rights to an experimental migraine drug.
Eli Lilly Chairman & CEO John Lechleiter discusses its loss of major patents, its current pipeline and when its total costs will normalize.
CNBC's Morgan Brennan reports on the FDA's four expediting pipelines. The approval rates for the drugs in these pipelines tend to be higher than those plodding the more traditional course.
Arena Co-Founder, Chairman, President and CEO Jack Lief talks to CNBC's Brian Sullivan about strategies for increasing weight-loss drug Belviq's prescriptions, from the JPM Health Care Conference in San Francisco.
Brian asks InterMune Chairman, President and CEO Dan Welch for an update on its drug Esbriet, and chances for U.S. approval.
Agios CEO David Schenkein on a new approach to cancer, and the outlook for product approval, from the JPMorgan Health Care Conference in San Francisco.
Chris Viehbacher, Sanofi CEO, discusses the $700 million deal Sanofi struck with Alnylam and the company's growth into the treatment of genetic diseases.
Accuray CEO Joshua Levine talks to CNBC's Brian Sullivan about his company's history of innovation and how it deals with larger competitors.
Brent Saunders, president and CEO at Forest Labs, explains how his company is taking the pharma world by storm and weighs in on several new products in the pipeline.
Dr. William Schaffner of Vanderbilt University School of Medicine, provides insight on a very resistant bacteria that affects patients mostly in hospitals. CNBC contributor Barbara Ryan, weighs in on the challenges facing the pharmaceutical companies.
Neurocrine Biosciences' president and CEO Kevin Gorman, Ph. D., provides insight on clinical trials for its tardive dyskinesia treatment.
CNBC's Bertha Coombs says a slowdown in the growth of health-care spending in 2012 isn't due to Obamacare, but it does provide a good base for comparisons in the future.
In late February, around 480 miles off the coast of Florida, the Cayman Islands will get ready to cater for a new kind of visitor.
Damien Conover, Equity Analyst at Morningstar talks about the impact of Obamacare on equity markets and highlights stocks that are set to benefit from it.
As a key enrollment deadline hits Monday, many people without health insurance are picking the cheapest one.
Barbara Ryan, FTI Consulting, discusses Glaxo's move to stop paying doctors to promote drugs.
CNBC's Sara Eisen reports GlaxoSmithKline is becoming the first to stop paying doctors to promote drugs.
James Wade, senior analyst at Datamonitor Healthcare, talks about the pharmaceuticals industry which faces a "big patent cliff" at the moment, and discusses the outlook for next year.
The announcement that GSK will stop paying doctors and remove sales incentives is a sea-change in an industry struggling with faltering sales.